Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- Conditions
- Childhood Germ Cell TumorOvarian CancerTeratoma
- Interventions
- Drug: carboplatinDrug: etoposideDrug: ifosfamideDrug: paclitaxelDrug: thiotepaProcedure: autologous hematopoietic stem cell transplantationDrug: MesnaBiological: filgrastim
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- ๐บ๐ธ
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: ifosfamideDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateDrug: vindesineRadiation: radiation therapy
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 4559
- Registration Number
- NCT00430118
- Locations
- ๐ฆ๐น
LKH Leoben, Leoben, Austria
๐ฆ๐นLandeskrankenhaus Feldkirch, Feldkirch-Tisis, Austria
๐ฆ๐นUniversitaet Kinderklinik, Graz, Austria
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00427791
- Locations
- ๐บ๐ธ
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
- Conditions
- Hemophagocytic Lymphohistiocytosis
- Interventions
- Drug: DexamethasoneDrug: EtoposideDrug: CyclosporinProcedure: Intrathecal therapyProcedure: Stem cell transplant
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 368
- Registration Number
- NCT00426101
- Locations
- ๐ธ๐ช
Childhood Cancer Research Unit, Karolinska Hospital, Stockholm, Sweden
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Nasser Hanna, M.D.
- Target Recruit Count
- 8
- Registration Number
- NCT00417248
- Locations
- ๐บ๐ธ
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
๐บ๐ธIndiana University Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธFort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Kรถrholz
- Target Recruit Count
- 648
- Registration Number
- NCT00416832
Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 30
- Registration Number
- NCT00416676
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Myelodysplasia-Related ChangesAdult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2AUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia
- Interventions
- Procedure: Autologous Bone Marrow TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DecitabineDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 546
- Registration Number
- NCT00416598
- Locations
- ๐บ๐ธ
Northwell Health NCORP, Lake Success, New York, United States
๐บ๐ธNorthwell Health/Center for Advanced Medicine, Lake Success, New York, United States
๐บ๐ธUniversity of Illinois, Chicago, Illinois, United States
G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients
- Conditions
- Small Cell Lung Cancer
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 85
- Registration Number
- NCT00401609
- Locations
- ๐ฎ๐น
Ospedale San Martino, Genova, GE, Italy
๐ฎ๐นDivisione di Oncologia Medica, U.S.L.L. 13, Noale, VE, Italy
๐ฎ๐นOspedale Umberto di Frosinone, Frosinone, FR, Italy
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLeukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: pegaspargaseDrug: methylprednisoloneDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- ๐จ๐ฆ
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
๐บ๐ธHerbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
๐จ๐ฆCentre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.